Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (11-20 of 221) with videos related to

Pageof 23
Sort By:
Cancer|May 6, 2024
Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?Lauren K Young, Balazs Halmos
Science Signaling|October 6, 2016
New twists in the AXL(e) of tumor progressionBalazs Halmos, Eric B Haura
Lung Cancer Management|August 11, 2020
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driverSo Yeon Kim, Balazs Halmos
Annals of Translational Medicine|July 11, 2020
Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?Fiona Mienko, Balazs Halmos, Haiying Cheng
Annals of Translational Medicine|October 24, 2017
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistanceShirin Attarian, Numa Rahman, Balazs Halmos
Annals of Translational Medicine|April 6, 2016
Has MET met its match?Alain Borczuk, Daniel Paucar, Balazs Halmos
Lung Cancer (Auckland, N.Z.)|October 27, 2017
<i>EGFR</i> T790M: revealing the secrets of a gatekeeperBrian Ko, Daniel Paucar, Balazs Halmos
Translational Lung Cancer Research|August 14, 2023
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tailAyse Ece Cali Daylan, Balazs Halmos
American Journal of Respiratory and Critical Care Medicine|August 1, 2015
Update in Lung Cancer 2014Avrum Spira, Balazs Halmos, Charles A Powell
American Journal of Respiratory and Critical Care Medicine|September 16, 2016
Update in Lung Cancer 2015Avrum Spira, Balazs Halmos, Charles A Powell
Pageof 23

Showing results (11-20 of 221) with videos related to

Sort By:
Pageof 23
Cancer|May 6, 2024
Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?Lauren K Young, Balazs Halmos
Science Signaling|October 6, 2016
New twists in the AXL(e) of tumor progressionBalazs Halmos, Eric B Haura
Lung Cancer Management|August 11, 2020
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driverSo Yeon Kim, Balazs Halmos
Annals of Translational Medicine|July 11, 2020
Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?Fiona Mienko, Balazs Halmos, Haiying Cheng
Annals of Translational Medicine|October 24, 2017
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistanceShirin Attarian, Numa Rahman, Balazs Halmos
Annals of Translational Medicine|April 6, 2016
Has MET met its match?Alain Borczuk, Daniel Paucar, Balazs Halmos
Lung Cancer (Auckland, N.Z.)|October 27, 2017
<i>EGFR</i> T790M: revealing the secrets of a gatekeeperBrian Ko, Daniel Paucar, Balazs Halmos
Translational Lung Cancer Research|August 14, 2023
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tailAyse Ece Cali Daylan, Balazs Halmos
American Journal of Respiratory and Critical Care Medicine|August 1, 2015
Update in Lung Cancer 2014Avrum Spira, Balazs Halmos, Charles A Powell
American Journal of Respiratory and Critical Care Medicine|September 16, 2016
Update in Lung Cancer 2015Avrum Spira, Balazs Halmos, Charles A Powell
Pageof 23